NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants with Germline RUNX1 Deficiency

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


predisposition to hematologic malignancies;
germline mutations;

Recruitment Keyword(s)



Inherited Bone Marrow Failure Syndrome;
familial platelet disorder with predisposition to myeloid malignancies

Investigational Drug(s)

Imatinib mesylate

Investigational Device(s)



Drug: imatinib
Device: TruSight Oncology

Supporting Site

National Cancer Institute


Runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations of this gene may bleed or bruise easily; they are also at higher risk of getting cancers of the blood, bone marrow, and lymph nodes.


To test a drug (imatinib) in people with RUNX1 mutations that cause symptoms.


Adults aged 18 and older with RUNX1 mutations. Healthy people without this mutation, including family members of affected participants, are also needed.


Participants with the RUNX1 mutation will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They may need a new bone marrow biopsy: A sample of soft tissue will be removed from inside a bone.

Imatinib is a tablet taken by mouth once a day, every day, at home. Affected participants in different parts of the study will take imatinib for either 28 days or up to 84 days.

Participants will visit the clinic once a week for the first 28 days that they are taking the imatinib. Then they will come once every 2 weeks if they are taking the drug for 84 days. Blood, urine, and tests of heart function will be repeated. They may opt to have the bone marrow biopsy repeated after they finish their course of imatinib.

Participants will have a follow-up visit 30 days after they stop taking imatinib.

Participants who do not have the RUNX1 mutation will have 1 clinic visit. They will have blood tests. They will fill out questionnaires. They may opt to have a bone marrow biopsy.

--Back to Top--



-Affected participants must have a confirmed pathogenic or likely pathogenic germline RUNX1 variant by history. ClinGen expert variant curation panel criteria for pathogenicity will be utilized.

-Affected participants must have a history of clinically significant bleeding as defined by history of abnormal ISTH-BAT score, use of anti-bleeding medications (e.g. amicar), history of platelet transfusion, abnormal PFA screen, abnotmal platelet aggregation or abnormal platelet electron microsopy.

-Normal bone marrow morphology, flow cytometry and cytogenetics confirmed by the NIH Department of Laboratory Medicine (DLM) at least within 9 months of initiating imatinib therapy.

-Normal TSO500 (a normal TSO500 result is defined as absence of secondary somatic mutations 5% or greater VAF) confirmed by NCI Lab of Path at the most recent biopsy at least within 9 months of initiating imatinib therapy.

-Reassuring TSO500 (a reassuring TSO500 result is defined as absence of pathogenic/likely pathogenic secondary somatic mutations 5% or greater VAF) confirmed by NCI Lab of Path at the most recent biopsy at least within 9 months of initiating imatinib therapy.

-Affected participants must be able to swallow pills and substantial GI malabsorption is not suspected

-Participants with human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial if their HAART medications do not interact with imatinib.

-Participants with evidence of chronic hepatitis B virus (HBV) infection, on suppressive therapy with undetectable HBV viral load are eligible for this trial. Suppressive therapy medication may not interact with imatinib.

-Participants with a distant history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment, with undetectable HCV viral load are eligible. If unknown HCV is detected upon screening- these participants will not be eligible for the study.


-Unaffected family members or healthy volunteers without RUNX1 mutation by pedigree or molecular testing Only participants who are related to the proband need to provide a molecular test.

-The last dosage of any platelet inhibiting medications was at least 2 weeks prior to enrollment and research sample acquisition.


-Age >=18 years.

-ECOG performance status <=2 (Karnofsky >=60%).

-Participants must have adequate organ and marrow function as defined below:

--leukocytes >= 3,000/mcL

--absolute neutrophil count >= 1,500/mcL

--platelets >= 65,000/mcL (without transfusion support)

--total bilirubin within normal institutional limits or <= 3 x the institutional upper limit of normal for participants with Gilbert s syndrome

--AST(SGOT)/ALT(SGPT) <= 2.5 x institutional upper limit of normal

--creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal.

---NIDDK CKD-EPI equation GFR = 141 x min (Scr /kappa, 1)^alpha x max(Scr /kappa, 1)^-1.209 x 0.993^Age x 1.018 [if female] x 1.159 [if black] where: Scr is serum creatinine in mg/dL, kappa is 0.7 for females and 0.9 for males, alpha is -0.329 for females and -0.411 for males, min indicates the minimum of Scr /kappa or 1, and max indicates the maximum of Scr /kappa or 1.

---Note: GFR is expressed in mL/min per 1.73 m^2, Scr is serum creatinine expressed in mg/dL, age is expressed in years, kappa is 0.7 for females and 0.9 for males, alpha is -0.329 for females and -0.411 for males, min indicates the minimum of Scr /kappa or 1, and max indicates the maximum of Scr /kappa or 1. Race is self-identified. Sex is defined as sex at birth and then self-identified after 12 months of hormone treatment for transgender individuals.

-Women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after the last administration of study drug.

-Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 30 days after the last administration of study drug

-Ability of participant to understand and the willingness to sign a written informed consent document.


-Participants who are receiving any other investigational agents.

-Participants who received prior hematologic malignancy directed therapy

-Participants receiving medication that would affect platelet number or function (e.g., aspirin and anti-platelet medications

-Participants without access to medical care at home.

-Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed in females of childbearing potential at screening).


-Participants with secondary somatic mutations of 5% VAF or greater on baseline Illumina TSO500 testing within a 30 day time period of receiving the first dose of imatinib

-History of allergic reactions attributed to compounds of similar chemical or biologic composition to imatinib or other agents used in study.

-Concomitant medications that include the following:

--Participants requiring medications which are inhibitors or inducers of CYP3A4 metabolism, as these may change imatinib plasma levels.

-Uncontrolled intercurrent illness evaluated by history, physical exam, and chemistries or situations that would limit compliance with study requirements, interpretation of results or that could increase risk to the participant

-Participants with the following cardiac conditions: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Lea C. Cunningham, M.D.
National Cancer Institute (NCI)
(301) 642-1633

Rebecca Alexander
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4-3152
10 Center Drive
Bethesda, Maryland 20892
(240) 781-4037

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--